FLAIR WEEK 96 RESULTS Page 1 Conference on Retroviruses and Opportunistic Infections;
March 8–11, 2020; Boston, MA CAB + RPV LA n=283, n (%) DTG/ABC/3TC n=283, n (%) HIV-1 …

Abstract Purpose of Review Despite the availability of safe and effective oral combination
antiretroviral therapy, barriers to maintaining viral suppression remain a challenge to ending …

Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of
HIV-1 infection brings promise of a new mode of delivery and potential solutions to some …

MOPEB258 Page 1 10th IAS Conference on HIV Science; July 21–24, 2019; Mexico City,
Mexico 71 43 38 32 31 332927 27 34 2420 0 20 40 60 80 100 4B 8 12 16 20 24 28 32 36 40 …

Background There is a need for more convenient, less frequent treatment to help address
challenges associated with daily oral HIV treatment in people living with HIV, including …

Introduction The development of long-acting (LA) drugs has changed the management of
common medical conditions for human replication immunodeficiency virus (HIV). Cabenuva …

Background Long-acting cabotegravir and rilpivirine administered monthly or every 2
months might address the challenges associated with daily oral antiretroviral therapy. The …

Background: Long-acting (LA) injectable antiretroviral therapy (ART) is a novel modality
currently under development as an alternative to daily oral ART. Objective: The LATTE-2 …

A regimen comprising extended release injectable suspensions of cabotegravir and
rilpivirine for concurrent administration (CABENUVA™) is being developed by ViiV …

Background: Long-acting (LA) injectable regimens are a potential therapeutic option in
people living with HIV-1. Setting: ATLAS (NCT02951052) and FLAIR (NCT02938520) were …